HIV-Infected Individuals

Pipeline Programs↗

Active Trials↗

Companies Involved↗

HIV-Infected Individuals is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

29/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

clinical trials

Completed12 · 57%

Terminated6 · 29%

Unknown status2 · 10%

Recruiting1 · 5%

Clinical Trials

Trial Activity

21 trials

Exploratory Study of LP-98 for Injection in ART-Naive HIV-Infected Individuals

Recruiting·SShanxi Kangbao Biological Product Co., Ltd.·Phase 1/2·NCT07433387·30 enrolled

Can Valacyclovir Attenuate Inflammation in Antiretroviral-Treated HIV-Infected Individuals With Herpes Simplex Virus Type 2?

Completed·UUniversity Health Network, Toronto·Phase 3·NCT01176409·60 enrolled

Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals

Completed·—·Phase 4·NCT04904406·81 enrolled

A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3

Completed·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000859·1,300 enrolled

3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals

Completed·RRockefeller University·Phase 1·NCT04250636·6 enrolled

Safety and Efficacy of Zidovudine for Asymptomatic HIV-Infected Individuals

Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000736·3,200 enrolled

A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.

Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000641·90 enrolled

Safety, Tolerance, Efficacy and Pharmacokinetics of Multiple Doses of sCD4-PE40 in the Treatment of HIV-Infected Individuals

Completed·PPharmacia and Upjohn·Phase 1·NCT00002087

HIV-1 Specific T -Cells (HST-NEETs) for HIV-Infected Individuals

Completed·—·Phase 1·NCT03485963·7 enrolled

3BNC117 and 10-1074 in HIV-infected Individuals

Completed·RRockefeller University·Phase 1·NCT02825797·34 enrolled

Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals

Completed·UUniversity of California, San Diego·N/A·NCT02251236·14 enrolled

MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy

Completed·MMacroGenics·Phase 1·NCT03570918·21 enrolled

A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells

Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000822·46 enrolled

Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals

Terminated·UUniversity of California, San Diego·N/A·NCT01293123·2 enrolled

Combination Therapy With VRC01 and 10-1074 in HIV-Infected Individuals Undergoing Sequential Treatment Interruptions

Terminated·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT03831945·27 enrolled

Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)